2015 | BioSenic

Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris

Read more about Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris

Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

Read more about Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million

Read more about Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million

Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015

Read more about Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015

Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA

Read more about Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA

Bone Therapeutics announces its financial calendar for 2015

Read more about Bone Therapeutics announces its financial calendar for 2015

Information on the total number of voting rights and shares

Read more about Information on the total number of voting rights and shares

Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial

Read more about Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial

Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial

Read more about Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial

Bone Therapeutics Establishes US Subsidiary

Read more about Bone Therapeutics Establishes US Subsidiary

Subscribe to 2015